News Column

Findings from Ohio State University Provides New Data on Breast Cancer (Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel,...

August 25, 2014



Findings from Ohio State University Provides New Data on Breast Cancer (Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III ...)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Researchers detail new data in Oncology. According to news reporting originating from Columbus, Ohio, by NewsRx correspondents, research stated, "This phase II trial tested the rate of pathologic complete response (pCR) achieved by women with stage II-III human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer (BC) treated with neoadjuvant nanoparticle albumin-bound paclitaxel (nab-P), carboplatin and bevacizumab. The rate of pCR was 18%, all pCRs were observed in patients with triple negative BC."

Our news editors obtained a quote from the research from Ohio State University, "We hypothesized that adding bevacizumab to neoadjuvant chemotherapy (NCT) with nab-P and carboplatin would increase the rates of pCR in BC patients and that early changes in tumor vascularity imaged by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict pCR. Thirty-three women with clinical stage II or III HER2-negative BC received nab-P 100 mg/m2 and carboplatin area under the curve = 2 on days 1, 8, and 15 in combination with bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days. Six patients (18%) achieved pCR, all pCRs occurred in triple-negative BC (TNBC) (pCR = 50% for TNBC). At the end of cycle 2, the changes in relative angiogenic volume were significantly different between responders and nonresponders (P = .001). The major toxicity of this NCT was myelosuppression. NCT with weekly nab-P, carboplatin, and biweekly bevacizumab resulted in a pCR rate that was neither superior to the historical data with anthracycline- or taxane-containing NCT nor to carboplatin and taxane combinations in patients with HER2-negative BC. In patients with TNBC, the observed pCR rate was 50%."

According to the news editors, the research concluded: "The early changes in the relative angiogenic volume imaged by DCE-MRI could predict pCR."

For more information on this research see: Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer. Clinical Breast Cancer, 2014;14(4):228-234. Clinical Breast Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Breast Cancer - www.elsevier.com/wps/product/cws_home/725535)

The news editors report that additional information may be obtained by contacting E. Mrozek, Ohio State University, Dept. of Radiol, Div Imaging Sci, Columbus, OH 43210, United States. Additional authors for this research include R. Layman, B. Ramaswamy, M. Lustberg, A. Vecchione, M.V. Knopp and C.L. Shapiro (see also Oncology).

Keywords for this news article include: Ohio, Taxoids, Therapy, Columbus, Oncology, Terpenes, Paclitaxel, Carboplatin, Angiogenesis, Hydrocarbons, United States, Breast Cancer, Cycloparaffins, Women's Health, Organic Chemicals, Organoplatinum Compounds, North and Central America, Clinical Trials and Studies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters